Full history for every metric is available with a Kvantra account

Stock profile
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
6.5B
Currency USD
KvantraRankAbout66
IValue76
IIQuality35
IIIMomentum94
Current price
95.81 USD-1.80%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m0000000-
Operating profit$m-122-183
Net profit$m-10-19-10-5-84-105-153-116
EPS reported$-2.31-2.41
Operating cashflow per share$-1.93-1.73
Capex per share$0.000.00
FCF per share$-1.94-1.73
Free cash flow$m-88-124
Net debt$m-335-917
Book value equity$m4721,197
Book value per share$10.3516.72
Number of sharesm45.6171.59
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx2.935.43
P/S LTMx0.000.00
P/FCF LTMx-15.64-52.46
EV/EBITDA LTMx-12.70-32.17
EV/Sales LTMx0.000.00
Earnings Yield LTM%-7.63%-2.23%
FCF Yield%-6.40%-1.91%
Quality
ROE%-22.34%-18.66%
ROIC%-25.76%-15.26%
Operating margin%0.00%0.00%
Gross margin%0.00%0.00%
FCF/Sales%--
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%--
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%-100.00%0.00%
Payout Ratio%--
FCF/Debtx-45.77-42.24
Net Debt/EBITDAx0.431.09
EBIT/Net interestx--
Net debt/market cap%-24.24%-14.12%
Net debt/Equityx-0.71-0.77
Gross debt/equityx0.000.00

ETFs that hold Oruka Therapeutics

FundTickerPosition#Weight
Invesco Dorsey Wright SmallCap Momentum ETFDWAS41.62%
ALPS Medical Breakthroughs ETFSBIO14.58%

Funds with Oruka Therapeutics among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price95.81 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Oruka Therapeutics, Inc. (ORKA)

ORKA · NASDAQ · Healthcare
95.81 USD-1.80%
Sign up to track this stock
Benchmarks
KvantraRank66
Market cap6.5B
P/E NTMN/A
P/E TTMN/A
KvantraRank?66 / 100
Value
76
Quality
35
Momentum
94
Financialsin USD
20242025TTM2026E
ETFs that hold Oruka Therapeutics
FundTickerPosition#Weight
Invesco Dorsey Wright SmallCap Momentum ETFDWAS41.62%
ALPS Medical Breakthroughs ETFSBIO14.58%

Funds with Oruka Therapeutics among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current95.81 USD
Upside
Price consensus
Last year average price target
Current price95.81 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free